IP Library › Granted Patent US 12,734,240
Granted Patent B1
US 12,734,240 · App. 19/076,021 · Granted Sep 15, 2026

Pharmaceutical composition and method of treating hematologic malignancies

Inventors: Max Temnik (Miami, FL); Victor Gurin (Richmond, VA); Sergey Gurin (Richmond, VA)
Assignee: ISM BIOSCIENCES LLC
A61K47/547A61K33/30A61P35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,734,240
App. No.
19/076,021
Granted
Sep 15, 2026
Kind
B1
Abstract

A method for treating hematologic malignancies comprises administration of a composition inclusive of 64 Zn e (Asp) in a therapeutically effective amount. Such administration may be via intravenous injection and/or infusion and may be once a day or more than once a day. Other identified compounds may be bound to 64 Zn e replacing L-Aspartate (Asp), provided that the resulting molecular weight does not exceed 700 Da and the resulting compound nanoparticles are less than 50.5 nm in size. The composition is suitable for intravenous injection and/or infusion.

Claims (3)

1 . A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64 Zn e (Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64 Zn e is administered to patient, wherein the 64 Zn e is at least 90% 64 Zn, and wherein aspartate is replaced by one or more of quercetin, apigenin, genistein, kaempferol, and chrysin, wherein the resulting molecule size is below 700 Da.

2 . A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of and wherein aspartate is replaced by one or more 64 Zn e (Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64 Zn e is administered to patient, wherein the 64 Zn e is at least 90% 64 Zn, and wherein aspartate is replaced by one or more of curcumin, epigallocatechin gallate, or resveratrol, wherein the resulting molecule size is below 700 Da.

3 . A pharmaceutical composition for suppressing leukemia, lymphoma, and myeloma malignancies including a therapeutically effective amount of 64 Zn e (Asp), wherein from 0.4 μg/kg patient weight to 1.682 g/kg patient weight of 64 Zn e is administered to patient, wherein the 64 Zn e is at least 90% 64 Zn, and wherein the composition includes a carrier selected from an ionophore, metallophore, polymeric micelle, metal organic framework, liposome, or a loaded platelet.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE TYPOGRAPHICAL ERROR IN THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 71103 FRAME 202. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 15, 2025
From: TEMNIK, MAX; GURIN, SERGEY; GURIN, VICTOR
To: ISM BIOSCIENCES LLC
Reel/Frame 071279/0890 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2025
From: GURIN, SERGEY; GURIN, VICTOR; TEMNIK, MAX
To: ISM BIOSCIENCESLLC
Reel/Frame 071103/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2025
From: TEMNIK, MAX; GURIN, SERGEY; GURIN, VICTOR
To: ISM BIOSCIENCES LLC
Reel/Frame 070969/0365 →
References Cited (71)
US 8491938B2 · Feng · 2013 [cited by applicant]
US 9861659B2 · Novak et al. · 2018 [cited by applicant]
US 10183041B2 · Novak et al. · 2019 [cited by applicant]
US 10221133B2 · Augeri et al. · 2019 [cited by applicant]
US 10226484B2 · Novak et al. · 2019 [cited by applicant]
US 10799530B1 · Novak et al. · 2020 [cited by applicant]
US 10857180B2 · Novak et al. · 2020 [cited by applicant]
US 10933091B1 · Novak et al. · 2021 [cited by applicant]
US 11286236B2 · Novak et al. · 2022 [cited by applicant]
US 11433095B1 · Novak et al. · 2022 [cited by applicant]
US 11484550B2 · Novak et al. · 2022 [cited by applicant]
US 11484610B2 · Novak et al. · 2022 [cited by applicant]
US 11504346B2 · Tomat et al. · 2022 [cited by applicant]
US 11596650B2 · Novak et al. · 2023 [cited by applicant]
US 11638721B2 · Novak et al. · 2023 [cited by applicant]
US 11730835B2 · Novak et al. · 2023 [cited by applicant]
US 11779597B2 · Novak et al. · 2023 [cited by applicant]
US 11827588B2 · Novak et al. · 2023 [cited by applicant]
US 11865184B2 · Krizhanovsky et al. · 2024 [cited by applicant]
US 11896610B2 · Novak et al. · 2024 [cited by applicant]
US 11944640B2 · Chung · 2024 [cited by applicant]
US 11986541B2 · Novak et al. · 2024 [cited by applicant]
US 12011458B2 · Novak et al. · 2024 [cited by applicant]
US 12036238B2 · Novak et al. · 2024 [cited by applicant]
US 12037309B2 · Novak et al. · 2024 [cited by applicant]
US 12097215B2 · Novak et al. · 2024 [cited by applicant]
US 12138322B2 · Novak et al. · 2024 [cited by applicant]
US 12233089B2 · Novak et al. · 2025 [cited by applicant]
US 12280065B2 · Kimball et al. · 2025 [cited by applicant]
US 12344626B2 · Kimball et al. · 2025 [cited by applicant]
US 20060040980A1 · Lind et al. · 2006 [cited by applicant]
US 20100172994A1 · Sigmund et al. · 2010 [cited by applicant]
US 20110117210A1 · Ugolkov · 2011 [cited by applicant]
US 20210187016A1 · Novak et al. · 2021 [cited by applicant]
US 20210322467A1 · Novak et al. · 2021 [cited by applicant]
US 20220313731A1 · Novak et al. · 2022 [cited by applicant]
US 20230061538A1 · Novak et al. · 2023 [cited by applicant]
US 20250032538A1 · Novak · 2025 [cited by applicant]
US 20250213609A1 · Chung · 2025 [cited by applicant]
US 20250375475A1 · Temnik et al. · 2025 [cited by applicant]
US 20260029404A1 · Temnik et al. · 2026 [cited by applicant]
GB 2597446A · 2022 [cited by applicant]
KR 100925516B1 · 2009 [cited by applicant]
WO 2009072120A1 · 2009 [cited by applicant]
WO WO2021126231A1 · 2021 [cited by examiner]
WO 2022203684A1 · 2022 [cited by applicant]
Novak et al., “In Vitro Anticancer Activity of the Light Stable Zinc Isotope (64Zn) Compounds,” Anticancer Research 42, 2002, pp. 5685-5698. [cited by applicant]
Perez Jesus et al., “Phase 1 First-in-Human Dose escalation and Dose Expansion Stud of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases,” Curesus, Oct. 4, 2022. [cited by applicant]
International Search Report and Written Opinion received in PCT/US2026/018394 mailed Jun. 2, 2026, pp. 1-8. [cited by applicant]
Schilling, Kathrin et all: “Investigations on Zinc Isotope Fractionation in Breast Cancer Tissue Using in vitro Cell Culture Uptake-Efflux Experiments” published on Jan. 20, 2022 in Frontiers in Medicine, https://www.fr… [cited by applicant]
Schilling, Kathrin et all: “Zinc stable isotopes in urine as diagnostic for cancer of secretory organs” published on May 12, 2021: https://pubmed.ncbi.nlm.nih.gov/33877364/. [cited by applicant]
Costello, Leslie et all: “Zinc: The Wonder Drug for the Treatment of Carcinomas” published on Jun. 25, 2020: https://pmc.ncbi.nlm.nih.gov/articles/PMC7316362/. [cited by applicant]
Hastuti, Agustina et all: “Cu and Zn isotope ratio variations in plasma for survival prediction in hematological malignancy cases” published on Oct. 2, 2020: https://pmc.ncbi.nlm.nih.gov/articles/PMC7532200/. [cited by applicant]
Zhang, Mengqi et all: “Isotope effect of 13C enriched testosterone on human cells” published on Feb. 16, 2022: https://www.spandidos-publications.com/10.3892/wasj.2022.144. [cited by applicant]
Karolinska Institutet et all: “Ultralight ultrafast enzymes: Isotopes more powerful than previously thought” published on Dec. 4, 2023: https://phys.org/news/2023-12-ultralight-ultrafast-enzymes-isotopes-powerful.html. [cited by applicant]
Guillin, Olivia et all: “Zinc Uptake by HIV-1 Viral Particles: An Isotopic Study” published on Oct. 16, 2023: https://www.mdpi.com/1422-0067/24/20/15274. [cited by applicant]
Cheng, Yunqi et all: “Aberrance of Zinc Metalloenzymes-Induced Human Diseases and Its Potential Mechanisms” published on Dec. 13, 2021: https://pmc.ncbi.nlm.nih.gov/articles/PMC8707169/. [cited by applicant]
Costa, Maria et all: “Zinc: From Biological Functions to Therapeutic Potential” published on Mar. 2, 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC10003636/. [cited by applicant]
Bendellaa, Mohamed et all: “Roles of zinc in cancers: From altered metabolism to therapeutic applications” published on Aug. 23, 2023: https://onlinelibrary.wiley.com/doi/10.1002/ijc.34679. [cited by applicant]
Wang, Jie et all: “Zinc dysregulation in cancers and its potential as a therapeutic target” published on Aug. 15, 2020: https://pmc.ncbi.nlm.nih.gov/articles/PMC7476080/. [cited by applicant]
Narayan, Sugandha et all “Zinc dampens antitumor immunity by promoting Foxp3+ regulatory T cells” published on Aug. 24, 2024: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024. 1389387/full. [cited by applicant]
Buj, Raquel et all: “CDKN2ALow cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistance” published in Bio Rx IV on Feb. 8, 2025, https://www.biorxiv.org/content/10.1101/2025.02.0… [cited by applicant]
Zhou, Xiao-Hong et all: “Targeting phosphatidylserine in tumor cell membranes with a zinc-containing molecule to efficiently combat tumor metastasis” published in Journal of Nanobiotechnology on May 20, 2025: https://pm… [cited by applicant]
Khalaji, Amirreza et all: “Don't eat me/eat me signals as a novel strategy in cancer immunotherapy” published in Heliyon on Sep. 29, 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC10562801/. [cited by applicant]
Xue, Jing et all: “Chloroquine Is a Zinc lonophore” published on Oct. 1, 2014: https://pmc.ncbi.nlm.nih.gov/articles/PMC4182877/. [cited by applicant]
Ekinci, Ilksen Berfin et all: “Ionophore Toxicity in Animals: A Review of Clinical and Molecular Aspects” published on Jan. 15, 2023: https://pmc.ncbi.nlm.nih.gov/articles/PMC9863538/. [cited by applicant]
Buchl, Anette et all: “Re-partitioning of Cu and Zn isotopes by modified protein expression” published on Oct. 10, 2008: https://pmc.ncbi.nlm.nih.gov/articles/PMC2570658/. [cited by applicant]
Burián, Z et all: “Selective Inhibition of HIF1a Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma” published on Apr. 26, 2020: https://pubmed.ncbi.nlm.nih.gov/30613921/. [cited by applicant]
U.S. Appl. No. 19/076,021, filed Mar. 11, 2024. [cited by applicant]
U.S. Appl. No. 19/068,709, filed Mar. 3, 2025. [cited by applicant]
Paredes, Eduardo et all: “Impact of uranium uptake on isotopic fractionation and endogenous element homeostasis in human neuron-like cells” published on Nov. 21, 2018: https://pmc.ncbi.nlm.nih.gov/articles/PMC6249223/. [cited by applicant]